Rohto Cooling Eye Drops Dry Aid (povidone 0.68%, propylene glycol 0.3%) recall — Rohto-mentholatum (vietnam) Co., Ltd. (Class II)

Rohto-mentholatum (vietnam) Co., Ltd. is recorded by the U.S. Food and Drug Administration (FDA) as recalling Rohto Cooling Eye Drops Dry Aid (povidone 0.68%, propylene glycol 0.3%) — a Class II recall, initiated 2026-07-14 and posted to the FDA enforcement report on 2026-07-29, under recall number D-0720-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Lack of Assurance of Sterility”. From the product description, the form is eye drops, the strengths given are 0.68%, 0.3% and 10 mL and the package is described as 0.34 FL OZ (10 mL). 1 National Drug Code number is printed in the record: 10742-8162-1, alongside UPC 310742011135. Distribution is recorded as “Nationwide within the United States” — Nationwide (US), with the recalling firm on record in N/A, Vietnam. The FDA files it under event ID 99440 together with 7 other recall numbers, all listed and linked below. Within that event this is the strength 0.68% · 0.3% · 10 mL, package 0.34 FL OZ (10 mL) and ndc 10742-8162-1 configuration; the sibling records differ on strength, package, ndc and product named and match on everything else the source states. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0720-2026
FDA event ID 99440 (8 recall numbers)
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Rohto-mentholatum (vietnam) Co., Ltd.
Recall initiated 2026-07-14
Reported by FDA 2026-07-29
Report lag 15 days from initiation to report
Distribution Nationwide within the United States — Nationwide (US)
Firm location on record N/A, Vietnam
Product description (source) Rohto Cooling Eye Drops Dry Aid (povidone 0.68%, propylene glycol 0.3%), Sterile, 0.34 FL OZ (10 mL), Distributed by: The Mentholatum Company, Orchard Park, NY 14127, Made in Vietnam, UPC 310742011135, NDC 10742-8162-1

Reason reported by FDA

Lack of Assurance of Sterility

5 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

9 identifying values matched by exact pattern in the 33-word product description above; each is a literal substring of it.

Product named Rohto Cooling Eye Drops Dry Aid (povidone 0.68%, propylene glycol 0.3%)
Form Eye Drops
Strength 0.68% · 0.3% · 10 mL
Package 0.34 FL OZ (10 mL)
NDC 10742-8162-1
UPC 310742011135
Stated origin Vietnam
Distributed by The Mentholatum Company, Orchard Park

Which configuration this record is

8 recall numbers share event 99440. They differ on strength, package, ndc and product named and agree on everything else the source states, so those are the values to check a package against.

Attribute This record (D-0720-2026) D-0715-2026D-0716-2026D-0717-2026D-0718-2026D-0719-2026D-0721-2026D-0722-2026
Strength 0.68% · 0.3% · 10 mL 0.2% · 0.05% · 0.25% · 13 mL0.03% · 0.2% · 13 mL0.03% · 0.2% · 13 mL0.03% · 0.5% · 0.2% · 13 mL0.35% · 0.05% · 13 mL0.68% · 0.3% · 10 mL0.012% · 0.2% · 13 mL
Package 0.34 FL OZ (10 mL) 0.4 FL OZ (13 mL)0.4 FL OZ (13 mL)TWIN PACK · 0.4 FL OZ (13 mL)0.4 FL OZ (13 mL)0.4 FL OZ (13 mL)TWIN PACK · 0.34 FL OZ (10 mL)0.4 FL OZ (13 mL)
NDC 10742-8162-1 10742-8146-110742-8158-110742-8158-210742-8160-110742-8175-110742-8162-210742-8141-1
Product named Rohto Cooling Eye Drops Dry Aid (povidone 0.68%, propylene glycol 0.3%) Rohto Cooling Eye Drops ALL-IN-ONE (hypromellose 0.2%, tetrahydrozoline HCL 0.05%, zinc sulfate 0.25%)Rohto Cooling Eye Drops Max Strength (naphazoline hydrochloride 0.03%, polysorbate 90, 0.2%)Rohto Cooling Eye Drops Max Strength (naphazoline hydrochloride 0.03%, polysorbate 80 0.2%)Rohto Cooling Eye Drops Optic Glow (naphazoline hydrochloride 0.03%, povidone 0.5%, propylene glycol 0.2%)Rohto Cooling Eye Drops Digi Eye (hypromellose 0.35%, tetrahydrozoline HCl 0.05%)Rohto Cooling Eye Drops Dry Aid (povidone 0.68%, propylene glycol 0.3%)Rohto Cooling Eye Drops Cool Relief (naphazoline hydrochloride 0.012%, polysorbate 80 0.2%)

Shared across all 8 records under this event: form Eye Drops; fda tier Class II; recalling firm Rohto-mentholatum (vietnam) Co., Ltd.; reason text Lack of Assurance of Sterility; initiated 2026-07-14; reported 2026-07-29.

Event context: 8 recall numbers under event 99440

One enforcement action, 8 recall numbers: the FDA filed 7 further configurations of this action under event 99440. Each keeps its own recall number and dates.

Recall recordRecall numberFDA tierStrength / formNDCReported
Rohto Cooling Eye Drops ALL-IN-ONE, 0.2%D-0715-2026Class II0.2% · Eye Drops10742-8146-12026-07-29
Rohto Cooling Eye Drops Max Strength, 0.03%D-0716-2026Class II0.03% · Eye Drops10742-8158-12026-07-29
Rohto Cooling Eye Drops Max Strength, 0.03%D-0717-2026Class II0.03% · Eye Drops10742-8158-22026-07-29
Rohto Cooling Eye Drops Optic Glow, 0.03%D-0718-2026Class II0.03% · Eye Drops10742-8160-12026-07-29
Rohto Cooling Eye Drops Digi Eye, 0.35%D-0719-2026Class II0.35% · Eye Drops10742-8175-12026-07-29
Rohto Cooling Eye Drops Dry Aid (povidone 0.68%, propylene glycol 0.3%)D-0721-2026Class II0.68% · Eye Drops10742-8162-22026-07-29
Rohto Cooling Eye Drops Cool Relief, 0.012%D-0722-2026Class II0.012% · Eye Drops10742-8141-12026-07-29

Reported in the same month (2026-07)

111 enforcement reports carry a report date in 2026-07; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Levothyroxine Sodium Tablets, 25 mcgD-0700-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 50 mcgD-0701-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 75 mcgD-0702-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 88 mcgD-0703-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 112 mcgD-0704-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 125 mcgD-0705-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 150 mcgD-0706-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 25 mcgD-0707-2026Major PharmaceuticalsClass II2026-07-29

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 1 nearest to 2026-07-29 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Levothyroxine Sodium Tablets, 50 mcgD-0708-2026Major Pharmaceuticals50 mcg · Tablets2026-07-29

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. A search on event 99440 returns all 8 of these recall numbers; a search on D-0720-2026 returns only this configuration. Match a package against 10742-8162-1 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Rohto-mentholatum (vietnam) Co., Ltd. (8 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0720-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0720-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-07-29
Ingested
2026-08-22
Record hash
708a316418feb135

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.